드림씨아이에스

223250KOSDAQ자연과학 및 공학 연구개발업

68.8 / 100

Reference Date: 2026-07-24

Financial Score33.5 / 40

News Sentiment21.3 / 25

Momentum4.0 / 20

Disclosure10.0 / 15

AI Analysis: PER is significantly undervalued vs. peers and PBR is significantly undervalued vs. peers is also solid. Declined 10.7% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

DreamCIS is a Contract Research Organization (CRO) that provides comprehensive services such as clinical trial design, data management, statistical analysis, and regulatory submissions for pharmaceutical companies. With over 25 years of experience and global expansion, the company is addressing growing demand for high-value drug development, including gene therapies and next-generation treatments.

Number of Employees

395people

Average Salary

55.1M KRW

Score Calculation Basis

Detailed Financial Score

PER

10.08Industry Average 43.648.0Point

Half of industry avg (excellent)

PBR

0.86Industry Average 2.527.0Point

Half of industry avg (excellent)

ROE

9.25Industry Average -32.093.5Point

Well below industry avg

Debt Ratio

2.75Industry Average 7.316.5Point

Half of industry avg (excellent)

Trend 2023~20258.5 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲18.1% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲111.0% (2-year basis)

ROE Trend

3.0 / 4

Avg ROE 8.2% (improving, 3yr)

Detailed News Sentiment

1 totalPositive 1Neutral 0Negative 0Average Sentiment Score 85

Positive
릴리·BMS 제주로…드림씨아이에스, 글로벌 투자 포럼 개최
드림씨아이에스가 글로벌 제약사들과 협력하여 K-바이오의 국제 진출을 지원하는 포럼 개최로 긍정적인 시장 반응 예상.

Detailed Momentum

52-week position1.0Point

Near 52w low (4%, downtrend)

Current 3,015Won52-week high 7,69052-week low 2,780

1-month return1.0Point

1m -10.67% (falling)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0

Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-06-26
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-06-26